Free tool · No account
Clinical trials for liver cancer
Liver cancer (hepatocellular carcinoma) trials weigh both the tumor and underlying liver function, so eligibility often turns on liver-health measures as much as the cancer itself.
1,008 recruiting trials. Showing a sample.
- recruitingPhase 2NCT06280508
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
Listed by the study for Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence. Record updated 2024-04-23.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFull details on ClinicalTrials.gov → - recruitingNCT03894917
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
This is an observational, prospective cohort study that will recruit a diverse sample of 84 participants with newly diagnosed with unresectable, advanced hepatocellular carcinoma (HCC) at the UT Health Cancer Center in San Antonio. This study uses geriatric assessment tools wi...
Listed by the study for Carcinoma, Hepatocellular. Record updated 2026-01-08.
Sponsored by The University of Texas Health Science Center at San AntonioFull details on ClinicalTrials.gov → - recruitingPhase 2NCT07493668
Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy
This is a Phase 2, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of fostrox in combination with lenvatinib compared with lenvatinib alone in patients with locally advanced or unresectable advanced hepatocellular carcinoma (HCC) who have...
Listed by the study for Hepatocellular Carcinoma (HCC). Record updated 2026-05-22.
Sponsored by CHA UniversityFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both p...
Listed by the study for Cholangiocarcinoma. Record updated 2026-08-24.
Sponsored by Astellas Pharma Global Development, Inc.Full details on ClinicalTrials.gov → - recruitingNCT06887348
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who rec...
Listed by the study for Hepatocellular Carcinoma. Record updated 2026-01-12.
Sponsored by Replimune, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 4NCT07150624
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with ...
Listed by the study for Hepatocellular Carcinoma (HCC). Record updated 2026-05-11.
Sponsored by Anhui Provincial HospitalFull details on ClinicalTrials.gov → - recruitingPhase 4NCT07486713
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Listed by the study for Cholangiocarcinoma. Record updated 2026-08-11.
Sponsored by Rigel PharmaceuticalsFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06858813
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events and change in disease activity when ABB...
Listed by the study for Hepatocellular Cancer. Record updated 2026-03-25.
Sponsored by AbbVieFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06560827
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
A Single-arm, Open-label, Multicenter, Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of CT011 Autologous CAR-T Cells in Patients with Hepatocellular Carcinoma at Risk of Recurrence after Surgical Resection.
Listed by the study for HCC. Record updated 2024-08-19.
Sponsored by CARsgen Therapeutics Co., Ltd.Full details on ClinicalTrials.gov → - recruitingPhase 4NCT06930573
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
This study is a single-arm, open-label study. To assess the efficacy and safety of AK112 therapy in patients with resectable hepatocellular carcinoma at high risk of recurrence. The primary endpoint is the 12-month RFS rate of resectable hepatocellular carcinoma.
Listed by the study for HCC. Record updated 2025-04-16.
Sponsored by The First Affiliated Hospital of Zhengzhou UniversityFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-09-16. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this liver cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.